Abstract. The present authors have recently demonstrated that hirsutine, one of the major alkaloids in Uncaria species, promotes cell apoptosis by inducing DNA damage and suppresses metastasis of breast cancer cells. Despite its potent anti-cancer activity, certain types of human breast cancer cells exhibit resistance to hirsutine. To maximize the clinical utility of hirsutine therapy against breast cancer, it is critical to explore the underlying mechanism that protects hirsutine-resistant breast cancer cell lines. To identify potential targets for overcoming hirsutine-resistance, the present study investigated a library of kinase inhibitors in combination with hirsutine treatment in the hirsutine-resistant human breast carcinoma MCF-7 cell line. Amongst the 96 compounds tested, inhibitors of the ataxia telangiectasia mutated (ATM) pathway sensitized MCF-7 cells to hirsutine-induced cell death along with a sustained DNA damage response. This sensitization of MCF-7 cells to the hirsutine-induced DNA damage response by interfering with the ATM pathway did not require p53. Instead, radical oxygen species generation was significantly increased in hirsute and ATM inhibitor-treated MCF-7 cells. In conclusion, the present findings suggest the importance of the ATM pathway for optimizing the anti-cancer effect of hirsutine in breast cancer cells.
Introduction
Breast cancer comprises the most commonly diagnosed type of cancer and one of the leading cause of cancer-induced mortality in women worldwide (1) . Despite current advances in therapeutic strategies against cancer, drug resistance remains a significant challenge; therefore, a combination of target-specific agents may be required to effectively eliminate these cells (2) . Chemotherapy is one of the most effective treatment strategies against cancer; however, cancer cells often acquire a resistance to chemotherapy, therefore continuing to grow and metastasize (3) . Hirsutine, one of the major alkaloids in Uncaria species, is known for its cardioprotective, antihypertensive and antiarrhythmic activity (4, 5) . The present authors previously demonstrated the anti-cancer effect of hirsutine in breast cancer cells (6, 7) ; however certain human breast cancer cell lines, including MCF-7, exhibited resistance against hirsutine-induced cytotoxicity.
The present study used a chemical screening approach and identified that the ataxia telangiectasia mutated (ATM) pathway is key for hirsutine-resistance in human breast carcinoma MCF-7 cells. The DNA damage response was significantly amplified in MCF-7 cells following co-treatment with hirsutine and KU-60019, a specific ATM inhibitor. While sensitization to hirsutine-induced DNA damage response in MCF-7 cells by interfering with the ATM pathway did not require p53, reactive oxygen species (ROS) generation was significantly increased in hirsute and ATM inhibitor-treated MCF-7 cells.
Materials and methods
Reagents. Hirsutine and a Cell Counting kit were purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan) and KU-60019 was purchased from AdooQ Bioscience LLC (Irvine, CA, USA). Muse™ Oxidative Stress kit was purchased from EMD Millipore (Billerica, MA, USA). The SCADS Inhibitor kit (No. 3) was provided by the Screening Committee of Anticancer Drugs (Tokyo, Japan). The expression vector for the p53 dominant negative mutant (pBABEpuro-p53DD) and pBABEpuro (control) were kindly gifted by Dr David E. Fisher (Massachusetts General Hospital, Boston, MA, USA).
Cell culture and stable transfection. Human breast carcinoma MCF-7 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% bovine serum (Nissui Pharmaceutical Co., Ltd., Tokyo, Japan). The cells were incubated at 37˚C in a humidified atmosphere of 95% air and 5% CO 2 . MCF-7 cells stably expressing dominant negative p53 were established as described previously (8) . Briefly, MCF-7 cells were transfected with pBABEpuro (control) or pBABEpuro-p53DD, which contains the p53 dominant negative mutant using Lipofectaimne 2000 (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The cells were selected by puromycin (100 µg/ml; Sigma-Ardrich, St. Louis, MO, USA) for 14 days. Subsequently, puromycin-resistant clones were isolated using sterilized cloning rings (Sigma-Ardrich) and expanded as established MCF-7 CTRL and MCF-7 p53DD cell lines. These cells were maintained in DMEM with puromycin (100 µg/ml). Dominant negative p53 expression was confirmed by western blot analysis.
Cell viability assay. MCF-7
CTRL , MCF-7 p53DD and MCF-7 cells were plated at a final concentration of 2x10 4 cells/well in a 96-well plate. After a 3 h incubation, the cells were treated with single or dual agents from the SCADs Inhibitor kit for 24 h. For a combination assay, all cells were pretreated with the inhibitor for 1 h. Following treatment, 10 µl WST-1 Cell Proliferation reagent (WST-1, Dojindo, Tokyo, Japan) was added. The 96-well plate was incubated for another 2 h in a humidified atmosphere (37˚C; 5% CO 2 ) to allow the formation of formazan dye and to obtain a higher sensitivity. The absorbance was measured in a microplate reader (Sunrise™; Tecan Group Ltd., Männedorf, Switzerland) at a wavelength of 450/620 nm. Cell viability was determined from the absorbance of soluble formazan dye generated by the living cells.
Western blot analysis. MCF-7
CTRL , MCF-7 p53DD and MCF-7 cells (American Type Culture Collection, Manassas, VA, USA) were exposed to single or dual agents for 0, 3, 6 and 12 h. Treated cells were collected, washed with phosphate buffered saline (PBS) and lysed in lysis buffer [25 mM HEPES (pH, 7.7), 0.3 M NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.1% Triton X-100, 20 mM β-glycerophosphate, 0.1 mM sodium orthovanadate, 0.5 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol, 10 mg/ml aprotinin, and 10 mg/ml leupeptin; Cell Signaling Technology, Danvers, MA USA]. The cell lysates were separated by 5-10% sodium dodecyl-sulfate polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes using a glycine transfer buffer [192 mM glycine, 25 mM Tris-HCl (pH, 8.8), and 20% (v/v) methanol; Sigma-Aldrich]. After blocking with Block Ace (DS Biomedical, Osaka, Japan) for 4 h at room temperature, the membrane was incubated overnight at 4˚C with primary antibodies, and subsequently for 60 min at room temperature with secondary antibodies. Primary and secondary antibodies were used at a dilution of 1:1,000 and 1:2,000, respectively, and the proteins were visualized with an Amersham ECL Western Blotting Detection kit (GE Healthcare Life Sciences, Chalfont, UK).
The following antibodies were purchased from Cell Signaling Technology, Inc.: Rabbit monoclonal anti-phospho-ATM (Ser1981; catalog no., 5883) and rabbit monoclonal anti-phospho-histone H2A.X (Ser139; catalog no., 9947). Goat polyclonal anti-actin (catalog no., sc-1615) and goat polyclonal anti-α-tubulin (catalog no., sc-31779) were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Mouse monoclonal anti-p53 (PAb421; catalog no., OP03) was purchased from Calbiochem ® (EMD Millipore).
ROS measurement. MCF-7 cells were grown in 12-well plates and cultured overnight to allow adherence. Subsequently, the cells were treated with single or dual agents for an additional 30 min. The cells were collected and washed twice with PBS and resuspended in 1X Assay Buffer and 190 µl oxidative stress working solution from the Muse™ Oxidative Stress kit were added to 10 µl cells. The cells were incubated at 37˚C for 30 min prior to analysis with a Muse™ Cell Analyzer (EMD Millipore). The assay was conducted in triplicate and in accordance to the manufacturer's protocol.
Statistical analysis. All data are expressed as the mean ± standard deviation of at least three independent experiments and were analyzed for statistical significance using the Student's t-test. Statistical analysis was performed using Microsoft Excel 2013 (Microsoft Corporation, Redmond, WA, USA) P<0.05 were considered to indicate a statistically significant difference.
Results
Protective role of the ATM pathway for hirsutine-induced cytotoxicity in MCF-7 cells. As previously reported, human epidermal growth factor (HER2) + /p53-mutated MDA-MB-453 and BT474 cell lines exhibit a response to hirsutine-induced cytotoxicity, whereas HER2 + /p53 wild-type MCF-7 cells exhibit significant resistance to hirsutine treatment (6, 7) . To investigate the potential molecular pathway that contribute to hirsutine resistance in MCF-7 cells, the present study evaluated the kinase inhibitor compounds in a SCADS Inhibitor kit, which are listed in Table I , and their effect on the viability of MCF-7 cells in combination with hirsutine treatment. As shown in Fig. 1 , ATM inhibitors exhibited a significant effect in sensitizing hirsutine-induced cytotoxicity in MCF-7 cells among the tested compounds. To additionally confirm the involvement of the ATM pathway in hirsutine resistance of MCF-7 cells, KU-60019, a second generation specific ATM inhibitor (9) (10) (11) , was tested at a non-toxic dose (~20 mM) on its own ( Fig. 2A ) and in combination with hirsutine (Fig. 2B) . As shown in Fig. 2B , KU-60019 exhibited a significant synergistic cytotoxic effect with hirsutine on MCF-7 cells (P<0.05 hirsutine treated cells vs. hirsutine and KU-60019 cells). mechanisms of hirsutine-induced cytotoxicity, the present study investigated whether a co-administration of hirsutine with KU-60019 also induces a DNA damage response in hirsutine-resistant MCF-7 cells. As shown in Fig. 3 , hirsutine did not induce persistent activation of the DNA damage response, as observed by the expression of γH2A.X in MCF-7 cell. Notably, treatment with KU-60019 alone did have an affect; combination of hirsutine and KU-60019 significantly induced the persistent DNA damage response along with the suppression of ATM activation. Taken together with the cytotoxicity data, the present study concludes that interference of the ATM pathway is an important mechanism for hirsutine-induced cytotoxicity by modulation of the DNA damage response. Hirsutine induces p53-independent DNA damage response and ROS generation in MCF-7 cells. Since p53 is a well known product of the DNA damage response, which induces cell death or repair and is expressed in hirsutine-resistant cell lines (12) , the importance of p53 in ATM-dependent hirsutine-resistance of MCF-7 cells was examined by the present study using MCF-7 cells that overexpressed dominant-negative p53 (MCF-7 p53DN cells; Fig. 4A ). While MCF-7 p53DN cells exhibited a higher sensitivity to irinotecan (Fig. 4B) , which is a typical DNA damage-inducing agent, no difference was observed in the response between hirsutine-treated MCF-7 p53DN and MCF-7 CTRL cells (Fig. 4C) . Therefore, the present study concludes that inhibition of the ATM pathway did not require p53 to confer hirsutine-resistance of MCF-7 cells. By contrast, it is known that mitochondrial activity and ROS generation are major contributors for the p53-independent DNA damage response (13) . Consequently, the ROS expression level in MCF-7 cells treated with hirsutine and KU-60019 was evaluated. As shown in Fig. 5 , the ROS expression level was significantly increased following co-treatment with hirsute and KU-60019 compared with cells treated with hirsutine or KU-60019 alone. Collectively, the present data indicate the potential utility of interfering with the ATM pathway to overcome hirsutine resistance by inducing p53-independent DNA damage response and ROS generation in MCF-7 cells.
Discussion
The DNA damage response is one molecular event that results in apoptosis, and consequently numerous anti-cancer agents induce a DNA damage response (14) (15) (16) (17) (18) . Hirsutine, one of the major alkaloids in Uncaria species, exhibits an anti-metastatic effect in a murine breast cancer model (6) and has an anti-tumor effect on HER2 + breast cancer cells by inducing DNA damage (7). However, certain breast cancer cell lines, primarily hormone receptor (estrogen or progesterone receptor) positive breast cancer MCF-7 and ZR-75-1 cells, have exhibited resistance to hirsutine-induced cytotoxicity and the DNA damage response in previous studies (6, 7) . The present study used a chemical screening approach, which identified that the ATM pathway is key for hirsutine-resistance in MCF-7 cells, and the DNA damage response is significantly amplified following co-treatment of hirsutine and KU-60019, a specific ATM inhibitor, in MCF-7 cells.
It has been widely recognized that the consequences resulting from the DNA damage response to induce cell death is counter regulated by the DNA repair response (12, 19, 20) . ATM kinases, key protein kinases for the DNA damage response, are known to regulate double-strand break repair (21, 22) . In response to low levels of DNA damage, ATM kinases activate p53 to induce cell cycle arrest leading to successful DNA repair (19) . In the present study, no difference was observed in the hirsutine response between p53 MCF-7 p53DN and control cells. Therefore, the present study concludes that the sensitization to hirsutine-induced DNA damage response in MCF-7 cells by interfering with the ATM pathway is independent of p53. In addition to the p53-dependent DNA repair response, the ATM-ROS pathway has been previously reported to amplify a DNA-damaging response following genotoxic stress (23) . In the present study, the level of ROS generation was significantly increased in MCF-7 cells treated with a combination of ATM inhibitor and hirsute. Considering p38 mitogen-activated protein kinase (MAPK) is known to be important in the DNA damage response induced by genotoxic stress with DNA-damaging chemotherapeutic agents (24) and a loss of ATM impairs the proliferation of stem cells through oxidative stress-mediated p38 MAPK signaling (25, 26) , the present study hypothesizes that p38 MAPK stress signaling pathway possibly contributes to the sensitization of MCF-7 cells to the hirsutine-induced DNA damage response by interfering with the ATM pathway.
The present results indicate the potential utility of interfering with the ATM pathway to overcome hirsutine resistance in breast cancer cells, which induces a p53-independent DNA damage response and ROS generation.
